Hims & Hers to Offer Eli Lilly's Weight-Loss Drugs
By Kelly Cloonan
Hims & Hers Health and Eli Lilly inked a deal for the telehealth platform to offer the pharmaceutical company's obesity drugs at self-pay prices, a move that comes amid fierce competition in the market for GLP-1 drugs.
Under the agreement, patients who receive a prescription from a provider on Hims & Hers' platform would get access to the same self-pay prices for Lilly's Zepbound and Foundayo that they would pay for the medicines elsewhere, the companies said.
For Lilly, the move allows it to tap into Hims & Hers' large user base as it looks to compete better with rival Novo Nordisk. Hims & Hers also has an agreement to offer Novo's Wegovy weight-loss drug at Novo's self-pay prices.
Lilly said adults with obesity have shown strong and growing interest in getting prescription medicines through telehealth providers.
"At Lilly, we are always looking for new ways to help more people get the medicines they need, and that means meeting patients where they already are," said Ilya Yuffa, president of Lilly USA and global customer capabilities.
Lilly said self-pay pricing starts at $149 a month for Foundayo and $299 a month for Zepbound.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
November 06, 2026 07:42 ET (12:42 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
3 of the Best Dividend Stocks to Own
These Overvalued Stocks Have Plenty of Room to Fall
4 Big Impacts from the US Midterm Elections for Investors
United States